Scienture Holdings Inc
SCNX
查看详细走势图
0.478USD
+0.048+11.07%
收盘 02/06, 16:00（美东）报价延迟15分钟
11.05M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+11.07%
5天
+5.13%
1月
-9.05%
6月
-80.02%
今年开始到现在
-6.35%
1年
-85.53%
查看详细走势图
TradingKey Scienture Holdings Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Scienture Holdings Inc当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在药品行业排名126/159位。机构持股占比非常高，中期看，股价处于下降通道。近一个月，市场表现较差，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Scienture Holdings Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Scienture Holdings Inc亮点
亮点风险
Scienture Holdings, Inc., through its wholly owned subsidiary, Scienture, LLC, is a specialty pharmaceutical company focused on providing enhanced value to patients, physicians and caregivers by offering specialty products to satisfy unmet market needs. Scienture, LLC is focused on developing and commercializing products for the treatment of central nervous system and cardiovascular diseases. Scienture LLC is developing a range of product candidates, including new potential treatments for hypertension, migraine, pain and thrombosis and other related disorders. The Company's product candidates include SCN- 102 (hypertension), SCN- 104 (CNS-Pain), SCN- 106 (Cardiovascular) and SCN- 107 (Pain). SCN-102 is an oral liquid formulation of losartan potassium in development for the treatment of hypertension. SCN-104 is a multi-dose pen-based delivery system for self-injection and increased patient convenience, which is in development for the acute treatment of migraine headaches.
业绩增长期
公司处于发展阶段，最新年度总收入136.64K美元
业绩转盈
公司业绩转盈，最新年度盈利美元
估值高估
公司最新PE估值-0.06，处于3年历史高位
机构减仓
最新机构持股1.16M股，环比减少24.50%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值606.15K
分析师目标
根据
0
位分析师
--
评级
--
目标均价
--
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Scienture Holdings Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Scienture Holdings Inc简介
Scienture Holdings, Inc., through its wholly owned subsidiary, Scienture, LLC, is a specialty pharmaceutical company focused on providing enhanced value to patients, physicians and caregivers by offering specialty products to satisfy unmet market needs. Scienture, LLC is focused on developing and commercializing products for the treatment of central nervous system and cardiovascular diseases. Scienture LLC is developing a range of product candidates, including new potential treatments for hypertension, migraine, pain and thrombosis and other related disorders. The Company's product candidates include SCN- 102 (hypertension), SCN- 104 (CNS-Pain), SCN- 106 (Cardiovascular) and SCN- 107 (Pain). SCN-102 is an oral liquid formulation of losartan potassium in development for the treatment of hypertension. SCN-104 is a multi-dose pen-based delivery system for self-injection and increased patient convenience, which is in development for the acute treatment of migraine headaches.
公司代码SCNX
公司Scienture Holdings Inc
CEOHariharan (Shankar)
网址
相关品种
